Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
Identifieur interne : 002741 ( Ncbi/Merge ); précédent : 002740; suivant : 002742Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
Auteurs : Andy Kilianski [États-Unis] ; Anna M. Mielech ; Xufang Deng ; Susan C. BakerSource :
- Journal of virology [ 1098-5514 ] ; 2013.
Descripteurs français
- KwdFr :
- Antiviraux (isolement et purification), Antiviraux (métabolisme), Coronavirus (), Coronavirus (enzymologie), Cysteine endopeptidases (métabolisme), Gènes rapporteurs, Humains, Inhibiteurs de protéases (isolement et purification), Inhibiteurs de protéases (métabolisme), Lignée cellulaire, Luciferases (analyse), Luciferases (génétique), Protéines virales (antagonistes et inhibiteurs), Protéines virales (métabolisme), Techniques de biocapteur (), Évaluation préclinique de médicament ().
- MESH :
- analyse : Luciferases.
- antagonistes et inhibiteurs : Protéines virales.
- enzymologie : Coronavirus.
- génétique : Luciferases.
- isolement et purification : Antiviraux, Inhibiteurs de protéases.
- métabolisme : Antiviraux, Cysteine endopeptidases, Inhibiteurs de protéases, Protéines virales.
- Coronavirus, Gènes rapporteurs, Humains, Lignée cellulaire, Techniques de biocapteur, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- Antiviral Agents (isolation & purification), Antiviral Agents (metabolism), Biosensing Techniques (methods), Cell Line, Coronavirus (drug effects), Coronavirus (enzymology), Cysteine Endopeptidases (metabolism), Drug Evaluation, Preclinical (methods), Genes, Reporter, Humans, Luciferases (analysis), Luciferases (genetics), Protease Inhibitors (isolation & purification), Protease Inhibitors (metabolism), Viral Proteins (antagonists & inhibitors), Viral Proteins (metabolism).
- MESH :
- chemical , analysis : Luciferases.
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , genetics : Luciferases.
- chemical , isolation & purification : Antiviral Agents, Protease Inhibitors.
- chemical , metabolism : Antiviral Agents, Cysteine Endopeptidases, Protease Inhibitors, Viral Proteins.
- drug effects : Coronavirus.
- enzymology : Coronavirus.
- methods : Biosensing Techniques, Drug Evaluation, Preclinical.
- Cell Line, Genes, Reporter, Humans.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with an outbreak of more than 90 cases of severe pneumonia with high mortality (greater than 50%). To date, there are no antiviral drugs or specific therapies to treat MERS-CoV. To rapidly identify potential inhibitors of MERS-CoV replication, we expressed the papain-like protease (PLpro) and the 3-chymotrypsin-like protease (3CLpro) from MERS-CoV and developed luciferase-based biosensors to monitor protease activity in cells. We show that the expressed MERS-CoV PLpro recognizes and processes the canonical CoV-PLpro cleavage site RLKGG in the biosensor. However, existing CoV PLpro inhibitors were unable to block MERS-CoV PLpro activity, likely due to the divergence of the amino acid sequence in the drug binding site. To investigate MERS-CoV 3CLpro activity, we expressed the protease in context with flanking nonstructural protein 4 (nsp4) and the amino-terminal portion of nsp6 and detected processing of the luciferase-based biosensors containing the canonical 3CLpro cleavage site VRLQS. Importantly, we found that a small-molecule inhibitor that blocks replication of severe acute respiratory syndrome (SARS) CoV and murine CoV also inhibits the activity of MERS-CoV 3CLpro. Overall, the protease expression and biosensor assays developed here allow for rapid evaluation of viral protease activity and the identification of protease inhibitors. These biosensor assays can now be used to screen for MERS-CoV-specific or broad-spectrum coronavirus PLpro and 3CLpro inhibitors.
DOI: 10.1128/JVI.02105-13
PubMed: 23986593
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001138
- to stream PubMed, to step Curation: 001138
- to stream PubMed, to step Checkpoint: 001224
Links to Exploration step
pubmed:23986593Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.</title><author><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de Chicago</orgName></affiliation></author><author><name sortKey="Mielech, Anna M" sort="Mielech, Anna M" uniqKey="Mielech A" first="Anna M" last="Mielech">Anna M. Mielech</name></author><author><name sortKey="Deng, Xufang" sort="Deng, Xufang" uniqKey="Deng X" first="Xufang" last="Deng">Xufang Deng</name></author><author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C" last="Baker">Susan C. Baker</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23986593</idno><idno type="pmid">23986593</idno><idno type="doi">10.1128/JVI.02105-13</idno><idno type="wicri:Area/PubMed/Corpus">001138</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001138</idno><idno type="wicri:Area/PubMed/Curation">001138</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001138</idno><idno type="wicri:Area/PubMed/Checkpoint">001224</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001224</idno><idno type="wicri:Area/Ncbi/Merge">002741</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.</title><author><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de Chicago</orgName></affiliation></author><author><name sortKey="Mielech, Anna M" sort="Mielech, Anna M" uniqKey="Mielech A" first="Anna M" last="Mielech">Anna M. Mielech</name></author><author><name sortKey="Deng, Xufang" sort="Deng, Xufang" uniqKey="Deng X" first="Xufang" last="Deng">Xufang Deng</name></author><author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C" last="Baker">Susan C. Baker</name></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (isolation & purification)</term><term>Antiviral Agents (metabolism)</term><term>Biosensing Techniques (methods)</term><term>Cell Line</term><term>Coronavirus (drug effects)</term><term>Coronavirus (enzymology)</term><term>Cysteine Endopeptidases (metabolism)</term><term>Drug Evaluation, Preclinical (methods)</term><term>Genes, Reporter</term><term>Humans</term><term>Luciferases (analysis)</term><term>Luciferases (genetics)</term><term>Protease Inhibitors (isolation & purification)</term><term>Protease Inhibitors (metabolism)</term><term>Viral Proteins (antagonists & inhibitors)</term><term>Viral Proteins (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (isolement et purification)</term><term>Antiviraux (métabolisme)</term><term>Coronavirus ()</term><term>Coronavirus (enzymologie)</term><term>Cysteine endopeptidases (métabolisme)</term><term>Gènes rapporteurs</term><term>Humains</term><term>Inhibiteurs de protéases (isolement et purification)</term><term>Inhibiteurs de protéases (métabolisme)</term><term>Lignée cellulaire</term><term>Luciferases (analyse)</term><term>Luciferases (génétique)</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Protéines virales (métabolisme)</term><term>Techniques de biocapteur ()</term><term>Évaluation préclinique de médicament ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Luciferases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Luciferases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antiviral Agents</term><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiviral Agents</term><term>Cysteine Endopeptidases</term><term>Protease Inhibitors</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Luciferases</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Luciferases</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Antiviraux</term><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biosensing Techniques</term><term>Drug Evaluation, Preclinical</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antiviraux</term><term>Cysteine endopeptidases</term><term>Inhibiteurs de protéases</term><term>Protéines virales</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Genes, Reporter</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Coronavirus</term><term>Gènes rapporteurs</term><term>Humains</term><term>Lignée cellulaire</term><term>Techniques de biocapteur</term><term>Évaluation préclinique de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with an outbreak of more than 90 cases of severe pneumonia with high mortality (greater than 50%). To date, there are no antiviral drugs or specific therapies to treat MERS-CoV. To rapidly identify potential inhibitors of MERS-CoV replication, we expressed the papain-like protease (PLpro) and the 3-chymotrypsin-like protease (3CLpro) from MERS-CoV and developed luciferase-based biosensors to monitor protease activity in cells. We show that the expressed MERS-CoV PLpro recognizes and processes the canonical CoV-PLpro cleavage site RLKGG in the biosensor. However, existing CoV PLpro inhibitors were unable to block MERS-CoV PLpro activity, likely due to the divergence of the amino acid sequence in the drug binding site. To investigate MERS-CoV 3CLpro activity, we expressed the protease in context with flanking nonstructural protein 4 (nsp4) and the amino-terminal portion of nsp6 and detected processing of the luciferase-based biosensors containing the canonical 3CLpro cleavage site VRLQS. Importantly, we found that a small-molecule inhibitor that blocks replication of severe acute respiratory syndrome (SARS) CoV and murine CoV also inhibits the activity of MERS-CoV 3CLpro. Overall, the protease expression and biosensor assays developed here allow for rapid evaluation of viral protease activity and the identification of protease inhibitors. These biosensor assays can now be used to screen for MERS-CoV-specific or broad-spectrum coronavirus PLpro and 3CLpro inhibitors. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23986593</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>21</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.</ArticleTitle><Pagination><MedlinePgn>11955-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02105-13</ELocationID><Abstract><AbstractText>Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with an outbreak of more than 90 cases of severe pneumonia with high mortality (greater than 50%). To date, there are no antiviral drugs or specific therapies to treat MERS-CoV. To rapidly identify potential inhibitors of MERS-CoV replication, we expressed the papain-like protease (PLpro) and the 3-chymotrypsin-like protease (3CLpro) from MERS-CoV and developed luciferase-based biosensors to monitor protease activity in cells. We show that the expressed MERS-CoV PLpro recognizes and processes the canonical CoV-PLpro cleavage site RLKGG in the biosensor. However, existing CoV PLpro inhibitors were unable to block MERS-CoV PLpro activity, likely due to the divergence of the amino acid sequence in the drug binding site. To investigate MERS-CoV 3CLpro activity, we expressed the protease in context with flanking nonstructural protein 4 (nsp4) and the amino-terminal portion of nsp6 and detected processing of the luciferase-based biosensors containing the canonical 3CLpro cleavage site VRLQS. Importantly, we found that a small-molecule inhibitor that blocks replication of severe acute respiratory syndrome (SARS) CoV and murine CoV also inhibits the activity of MERS-CoV 3CLpro. Overall, the protease expression and biosensor assays developed here allow for rapid evaluation of viral protease activity and the identification of protease inhibitors. These biosensor assays can now be used to screen for MERS-CoV-specific or broad-spectrum coronavirus PLpro and 3CLpro inhibitors. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kilianski</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielech</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xufang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Susan C</ForeName><Initials>SC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI085089</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI007508</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AI085089</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI512795</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="C052731">3C proteases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015374" MajorTopicYN="N">Biosensing Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23986593</ArticleId><ArticleId IdType="pii">JVI.02105-13</ArticleId><ArticleId IdType="doi">10.1128/JVI.02105-13</ArticleId><ArticleId IdType="pmc">PMC3807373</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biochem Soc Trans. 2011 Oct;39(5):1371-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21936817</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Dec;79(24):15189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">16306590</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2009 Jun;7(6):439-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19430490</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):480-3</Citation><ArticleIdList><ArticleId IdType="pubmed">23760190</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2008;454:3-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19057882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 Jun 29;381(9885):2265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23727167</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Biol. 2005 Oct;3(10):e324</Citation><ArticleIdList><ArticleId IdType="pubmed">16128623</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Jun 27;368(26):2487-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23718156</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Biotechnol. 2009 Feb;20(1):14-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19299118</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2012;3(6). pii: e00473-12. doi: 10.1128/mBio.00473-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Jul;83(13):6689-705</Citation><ArticleIdList><ArticleId IdType="pubmed">19369340</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(6):e66248</Citation><ArticleIdList><ArticleId IdType="pubmed">23776643</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(11):e27228</Citation><ArticleIdList><ArticleId IdType="pubmed">22073294</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013;346:f3114</Citation><ArticleIdList><ArticleId IdType="pubmed">23674339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Biol. 2008 Jun;15(6):597-606</Citation><ArticleIdList><ArticleId IdType="pubmed">18559270</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Cell. 2013 Apr;4(4):248-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23549610</ArticleId></ArticleIdList></Reference><Reference><Citation>Peptides. 2006 Apr;27(4):622-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16242214</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2010 Jul 8;53(13):4968-79</Citation><ArticleIdList><ArticleId IdType="pubmed">20527968</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Jul;87(14):7790-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23678167</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18852458</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Virol. 2011 May;6(5):615-631</Citation><ArticleIdList><ArticleId IdType="pubmed">21765859</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Biol. 2011 Nov 18;6(11):1193-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21932825</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2008 Oct 15;18(20):5684-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18796354</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2011 Apr;90(1):9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21316392</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012;17(49). pii: 20334</Citation><ArticleIdList><ArticleId IdType="pubmed">23231891</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Jul;77(13):7376-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12805436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Mar;82(5):2515-27</Citation><ArticleIdList><ArticleId IdType="pubmed">18094151</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16581910</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2013 Jan 24;56(2):534-46</Citation><ArticleIdList><ArticleId IdType="pubmed">23231439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region><settlement><li>Chicago</li></settlement><orgName><li>Université de Chicago</li></orgName></list><tree><noCountry><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C" last="Baker">Susan C. Baker</name><name sortKey="Deng, Xufang" sort="Deng, Xufang" uniqKey="Deng X" first="Xufang" last="Deng">Xufang Deng</name><name sortKey="Mielech, Anna M" sort="Mielech, Anna M" uniqKey="Mielech A" first="Anna M" last="Mielech">Anna M. Mielech</name></noCountry><country name="États-Unis"><region name="Illinois"><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002741 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002741 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:23986593
|texte= Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:23986593" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |